Figures & data
Table 1. Quantities of material used for SLM formulation.
Table 2. Properties of the SLMs formulation.
Table 3. Anti-inflammatory activity and time-resolved pH analysis.
Figure 1. Photomicrographs of SLM-0 (0 mg DicNa) SLM-1 (25 mg DicNa), SLM-2 (50 mg DicNa), SLM-3 (75 mg DicNa) and SLM-4 (100 mg DicNa) after 2 weeks of preparation. Bar represents 65.0 μm.
![Figure 1. Photomicrographs of SLM-0 (0 mg DicNa) SLM-1 (25 mg DicNa), SLM-2 (50 mg DicNa), SLM-3 (75 mg DicNa) and SLM-4 (100 mg DicNa) after 2 weeks of preparation. Bar represents 65.0 μm.](/cms/asset/8c62326c-162d-452b-9ad9-3ae65368b31b/idrd_a_923062_f0001_c.jpg)
Figure 2. Particle-size distribution of formulations a SLM-1 to SLM-4 containing 25, 50, 75 and 100 mg of diclofenac sodium, respectively. SLM-0 is the unloaded formulation.
![Figure 2. Particle-size distribution of formulations a SLM-1 to SLM-4 containing 25, 50, 75 and 100 mg of diclofenac sodium, respectively. SLM-0 is the unloaded formulation.](/cms/asset/38e2ddc0-604a-43e8-bf0e-8670174dbd5b/idrd_a_923062_f0002_c.jpg)
Figure 3. In vitro release profile of DicNa from SLM formulated in phosphate buffer (pH 7.4) system. SLM-1 to SLM-4 contains 25, 50, 75 and 100 mg of DicNa, respectively.
![Figure 3. In vitro release profile of DicNa from SLM formulated in phosphate buffer (pH 7.4) system. SLM-1 to SLM-4 contains 25, 50, 75 and 100 mg of DicNa, respectively.](/cms/asset/d3e09523-167e-4167-a77a-4946a6a36fb5/idrd_a_923062_f0003_c.jpg)
Figure 4. Mean ulcer index (±SD) of SLM-0 to SLM-4 containing 0, 25, 50, 75 and 100 mg of DicNa, respectively. PS represent the pure sample (diclofenac sodium) as a positive control.
![Figure 4. Mean ulcer index (±SD) of SLM-0 to SLM-4 containing 0, 25, 50, 75 and 100 mg of DicNa, respectively. PS represent the pure sample (diclofenac sodium) as a positive control.](/cms/asset/e10e9fe4-5f68-479e-8dc8-e26aaf88e77f/idrd_a_923062_f0004_c.jpg)
Figure 5. Percentage GI protection of SLM-0 to SLM-4 containing 0, 25, 50, 75 and 100 mg of DicNa, respectively. PS represent the pure drug sample as a positive control.
![Figure 5. Percentage GI protection of SLM-0 to SLM-4 containing 0, 25, 50, 75 and 100 mg of DicNa, respectively. PS represent the pure drug sample as a positive control.](/cms/asset/2b5288b7-5fb5-4b65-9530-e4ae18e11952/idrd_a_923062_f0005_c.jpg)
Figure 6. Plasma concentration versus time plotting of DicNa after oral administration of SLM-4, PS and MKT-S within 18 h (mean ± SD, n = 3). DicNa = diclofenac sodium, SLM-4 = batch 4 of the diclofenac sodium-loaded SLMs, PS = pure drug and MKT-S = market sample of diclofenac sodium.
![Figure 6. Plasma concentration versus time plotting of DicNa after oral administration of SLM-4, PS and MKT-S within 18 h (mean ± SD, n = 3). DicNa = diclofenac sodium, SLM-4 = batch 4 of the diclofenac sodium-loaded SLMs, PS = pure drug and MKT-S = market sample of diclofenac sodium.](/cms/asset/33330749-c3d8-4aec-9b57-f68a0a0dc489/idrd_a_923062_f0006_c.jpg)